Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAd63 ME-TRAP
- Development stage
- Phase 2
- Lead developer
- University of Oxford
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChAd63 ME-TRAP is an investigational malaria vaccine that uses a heterologous prime-boost strategy with two viral vectors—chimpanzee adenovirus 63 (ChAd63) and Modified Vaccinia Virus Ankara (MVA)—to deliver the multiepitope string fused to thrombospondin-related adhesion protein (ME-TRAP) antigen. The vaccine is designed to induce strong T-cell responses against *Plasmodium falciparum*, targeting the liver stage of the parasite's lifecycle. Clinical trials have shown that while it is safe and immunogenic in both adults and children exposed to malaria, its efficacy in preventing clinical malaria has been limited in highly endemic settings[1][3][5]. The vaccine regimen aims to reduce liver-stage parasite burden by eliciting robust cellular immune responses, particularly IFN-gamma–producing T cells[2][6]. It remains under clinical investigation for malaria prevention.
- Other names
- ChAd63-MVA ME-TRAPChAd-63-MVA ME-TRAPChAd 63-MVA ME-TRAP
02
Targets
TRAP (Thrombospondin-related anonymous protein)
Beyond the preview
Go deeper on ChAd63 ME-TRAP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAd63 ME-TRAP.